Annual EBITDA
-$61.98 M
-$321.00 K-0.52%
31 December 2023
Summary:
Rani Therapeutics Holdings annual earnings before interest, taxes, depreciation & amortization is currently -$61.98 million, with the most recent change of -$321.00 thousand (-0.52%) on 31 December 2023. During the last 3 years, it has fallen by -$46.02 million (-288.44%). RANI annual EBITDA is now -288.44% below its all-time high of -$15.96 million, reached on 31 December 2020.RANI EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$11.13 M
+$704.00 K+5.95%
30 September 2024
Summary:
Rani Therapeutics Holdings quarterly earnings before interest, taxes, depreciation & amortization is currently -$11.13 million, with the most recent change of +$704.00 thousand (+5.95%) on 30 September 2024. Over the past year, it has increased by +$5.67 million (+33.77%). RANI quarterly EBITDA is now -335.29% below its all-time high of -$2.56 million, reached on 30 June 2020.RANI Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$48.73 M
+$5.67 M+10.43%
30 September 2024
Summary:
Rani Therapeutics Holdings TTM earnings before interest, taxes, depreciation & amortization is currently -$48.73 million, with the most recent change of +$5.67 million (+10.43%) on 30 September 2024. Over the past year, it has increased by +$17.21 million (+26.10%). RANI TTM EBITDA is now -839.55% below its all-time high of -$5.19 million, reached on 31 March 2020.RANI TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RANI EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -0.5% | +33.8% | +26.1% |
| 3 y3 years | -288.4% | +60.9% | -9.8% |
| 5 y5 years | - | - | - |
RANI EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -288.4% | at low | at high | +60.9% | -9.8% | +31.4% |
| 5 y | 5 years | -288.4% | at low | -335.3% | +60.9% | -839.5% | +31.4% |
| alltime | all time | -288.4% | at low | -335.3% | +60.9% | -839.5% | +31.4% |
Rani Therapeutics Holdings EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$11.13 M(-6.0%) | -$48.73 M(-10.4%) |
| June 2024 | - | -$11.83 M(-10.6%) | -$54.40 M(-9.0%) |
| Mar 2024 | - | -$13.24 M(+5.6%) | -$59.78 M(-3.5%) |
| Dec 2023 | -$61.98 M(+0.5%) | -$12.53 M(-25.4%) | -$61.98 M(-6.0%) |
| Sept 2023 | - | -$16.80 M(-2.4%) | -$65.93 M(+1.5%) |
| June 2023 | - | -$17.21 M(+11.5%) | -$64.96 M(+2.4%) |
| Mar 2023 | - | -$15.44 M(-6.4%) | -$63.44 M(+2.9%) |
| Dec 2022 | -$61.66 M | -$16.49 M(+4.2%) | -$61.66 M(+5.6%) |
| Sept 2022 | - | -$15.82 M(+0.8%) | -$58.40 M(-17.8%) |
| June 2022 | - | -$15.69 M(+14.9%) | -$71.01 M(+17.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$13.65 M(+3.2%) | -$60.51 M(+16.2%) |
| Dec 2021 | -$52.08 M(+226.4%) | -$13.23 M(-53.5%) | -$52.08 M(+17.3%) |
| Sept 2021 | - | -$28.43 M(+448.2%) | -$44.40 M(+138.3%) |
| June 2021 | - | -$5.19 M(-0.8%) | -$18.63 M(+16.4%) |
| Mar 2021 | - | -$5.23 M(-5.6%) | -$16.00 M(+0.3%) |
| Dec 2020 | -$15.96 M(-38.7%) | -$5.54 M(+107.6%) | -$15.96 M(+53.2%) |
| Sept 2020 | - | -$2.67 M(+4.5%) | -$10.41 M(+34.5%) |
| June 2020 | - | -$2.56 M(-50.7%) | -$7.74 M(+49.3%) |
| Mar 2020 | - | -$5.19 M | -$5.19 M |
| Dec 2019 | -$26.01 M | - | - |
FAQ
- What is Rani Therapeutics Holdings annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Rani Therapeutics Holdings?
- What is Rani Therapeutics Holdings annual EBITDA year-on-year change?
- What is Rani Therapeutics Holdings quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Rani Therapeutics Holdings?
- What is Rani Therapeutics Holdings quarterly EBITDA year-on-year change?
- What is Rani Therapeutics Holdings TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Rani Therapeutics Holdings?
- What is Rani Therapeutics Holdings TTM EBITDA year-on-year change?
What is Rani Therapeutics Holdings annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of RANI is -$61.98 M
What is the all time high annual EBITDA for Rani Therapeutics Holdings?
Rani Therapeutics Holdings all-time high annual earnings before interest, taxes, depreciation & amortization is -$15.96 M
What is Rani Therapeutics Holdings annual EBITDA year-on-year change?
Over the past year, RANI annual earnings before interest, taxes, depreciation & amortization has changed by -$321.00 K (-0.52%)
What is Rani Therapeutics Holdings quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of RANI is -$11.13 M
What is the all time high quarterly EBITDA for Rani Therapeutics Holdings?
Rani Therapeutics Holdings all-time high quarterly earnings before interest, taxes, depreciation & amortization is -$2.56 M
What is Rani Therapeutics Holdings quarterly EBITDA year-on-year change?
Over the past year, RANI quarterly earnings before interest, taxes, depreciation & amortization has changed by +$5.67 M (+33.77%)
What is Rani Therapeutics Holdings TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of RANI is -$48.73 M
What is the all time high TTM EBITDA for Rani Therapeutics Holdings?
Rani Therapeutics Holdings all-time high TTM earnings before interest, taxes, depreciation & amortization is -$5.19 M
What is Rani Therapeutics Holdings TTM EBITDA year-on-year change?
Over the past year, RANI TTM earnings before interest, taxes, depreciation & amortization has changed by +$17.21 M (+26.10%)